Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, By Region, And Segment Forecasts, 2024

Description

Immuno-oncology Clinical Trials Market Growth & Trends:

The global immuno-oncology clinical trials market size is expected to reach USD 18.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.1% from 2024 to 2030. The rapidly growing field of Immuno-oncology has emerged as a novel therapeutic area within the oncology ecosystem, transforming the treatment of cancer.

From 2014 to 2017, the number of new immuno-oncology studies increased from 250 to almost 600, with double-digit growth rates each year as drug classes diversified. Biomarker and checkpoint inhibitor studies were primarily responsible for this rapid growth. While the immuno-oncology market is maturing in some pharmacological classes, cell therapies are exceeding all other immunotherapeutics in terms of growth. In March 2020, there were 1,483 active compounds in the pipeline for cancer cell therapy globally, indicating an increase of 472 from March 2019. The fastest-growing category was chimeric antigen receptor T (CAR-T) cell products (up 77% from 2019 to 2020).

Besides, during the Covid-19 pandemic, the number of IO drugs in development increased from 3,876 in 2019 to 4,720 in 2020, representing a 22% & 233% increase as compared to 2019 & 2017 respectively. After a moderate increase of 15% in 2019 compared to 68% between 2018 and 2017, this 22% increase indicates a return of interest in IO, despite the impact of the COVID-19 pandemic.

Immuno-oncology Clinical Trials Market Report Highlights:

Phase III dominated the market with the largest share of 53.2% in 2023. Oncology trials typically have fewer participants, are the most expensive, and involve larger sample sizes, resulting in a higher cost per participant.
The interventional experiments accounted for more than 78.5% of the market share in 2023
The segment of solid tumors held 55.9% of the revenue share in 2023. This is largely attributed to the rise in the prevalence of solid tumors
North America dominated the market and accounted for the largest revenue share of 50.3% in 2020. This is due to the rising adoption of personalized medicine-focused novel treatment methods, as well as the government funding and investments

Product Code: GVR-4-68038-273-0

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Immuno-oncology Clinical Trials Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Immuno-oncology Clinical Trials Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Immuno-oncology Clinical Trials Market: Phase Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Immuno-oncology Clinical Trials Market: Phase Movement Analysis, USD Billion, 2023 & 2030
- 4.2.1. Phase I
  - 4.2.1.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.2.2. Phase II
  - 4.2.2.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.2.3. Phase III
  - 4.2.3.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.2.4. Phase IV
  - 4.2.4.1. Phase IV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Immuno-oncology Clinical Trials Market: Design Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Immuno-oncology Clinical Trials Market: Design Movement Analysis, USD Billion, 2023 & 2030
- 5.2.1. Interventional Trials
  - 5.2.1.1. Interventional Trials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.2.2. Observational Trials
  - 5.2.2.1. Observational Trials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.2.3. Expanded Access Trials
  - 5.2.3.1. Expanded Access Trials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Immuno-oncology Clinical Trials Market: Indication Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Immuno-oncology Clinical Trials Market: Indication Movement Analysis, USD Billion, 2023 & 2030
- 6.2.1. Solid Tumors
  - 6.2.1.1. Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.2.2. Hematological Cancer Healthcare
  - 6.2.2.1. Hematological Cancer Healthcare Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Immuno-oncology Clinical Trials Market: Regional Estimates & Trend Analysis

7.1. Immuno-oncology Clinical Trials Market Share, By Region, 2023 & 2030, USD Billion
7.2. North America
- 7.2.1. North America Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.2.3. Canada
  - 7.2.3.1. Canada Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3. Europe
- 7.3.1. Europe Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.2. UK
  - 7.3.2.1. U.K. Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.3. Germany
  - 7.3.3.1. Germany Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.4. France
  - 7.3.4.1. France Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.5. Italy
  - 7.3.5.1. Italy Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.6. Spain
  - 7.3.6.1. Spain Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.9. Norway
  - 7.3.9.1. Norway Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.2. Japan
  - 7.4.2.1. Japan Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.3. China
  - 7.4.3.1. China Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.4. India
  - 7.4.4.1. India Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.5. Australia
  - 7.4.5.1. Australia Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.6. South Korea
  - 7.4.6.1. South Korea Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Latin America
- 7.5.1. Latin America Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Saudi Arabia Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.4. UAE
  - 7.6.4.1. UAE Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. MEDPACE
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/Strategic Initiatives
- 8.4.2. Novartis
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/Strategic Initiatives
- 8.4.3. Exscientia
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/Strategic Initiatives
- 8.4.4. Syneous Health
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/Strategic Initiatives
- 8.4.5. AstraZeneca
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/Strategic Initiatives
- 8.4.6. IQ BIOTECH
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/Strategic Initiatives
- 8.4.7. BioNtech
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/Strategic Initiatives
- 8.4.8. IQVIA Holdings
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/Strategic Initiatives
- 8.4.9. ICON, Plc
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/Strategic Initiatives
- 8.4.10. Laboratory Corporation of America Holdings
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/Strategic Initiatives

Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, By Region, And Segment Forecasts, 2024 - 2030